Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 620 participants.

Also called NCT04504396

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 620 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04504396
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04504396. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-23 (actual); primary completion 2022-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
GLP-1 receptor agonist
Intervention (Drug)
Placebo
Lead sponsor
PegBio Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct04504396
Content hash
6e583262cd5fcaa1991a9d162c099964c2f6b42c85477650144f93bdf07b6420